Table 2.
First-line treatment and response to first-line treatment
| Characteristics | Male n=64 (47%) | Female n=72 (53%) | 70–80 y n=91 (67%) | >80 y n=45 (33%) | Statistics (<80 vs. >80) | Total n=136 (100%) |
|---|---|---|---|---|---|---|
| CHOP21 or equivalent | 50 (78%) | 58 (80%) | 78 (86%) | 30 (67%) |
p= 0.01 (CHOP vs. palliative or no treatment) p=0.08 (CHOP started vs. CHOP completed) |
108 (79%) |
| Completion of CHOP treatment, if intended | 39 (78%) | 37 (64%) | 58 (74%) | 18 (60%) | 76 (70%) | |
| Palliative or no treatment | 14 (22%) | 14 (19%) | 13 (14%) | 15 (33%) | 28 (21%) | |
| Response to first-line treatment, CHOP or equivalent, n (%) | ||||||
| CR | 26 (52%) | 37 (64%) | 50 (64%) | 13 (43%) | p= 0.08 (response CR vs. <CR) | 63 (58%) |
| PR | 19 (38%) | 12 (21%) | 22 (28%) | 9 (30%) | 31 (29%) | |
| SD or PD | 5 (10%) | 9 (16%) | 6 (8%) | 8(27%) | 14 (13%) | |
| PFS, median (years) | 4.1 | 2.9 | 4.83 | 1.09 | 3.44 | |
| OS, median (years) | 7.9 | 7.3 | 6.3 | 7.9 | 7.38 | |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival; palliative regimen comprises rituximab, bendamustine (BR); rituximab, cyclophosphamide, vincristine, prednisone (R-CVP); rituximab, vincristine, prednisone (R-VIP), best supportive care (BSC)